The discovery of epidepride and its analogs as high-affinity radioligands for imaging extrastriatal dopamine D(2) receptors in human brain.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Current pharmaceutical design

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  PMID 12570798
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of remoxipride and some related new substituted salicylamides on rat brain receptors.

  2009cited by this paper
• SPECT imaging of dopamine receptors with [123I]epidepride: characterization of uptake in the human brain

  2005cited by this paper
• Regional distribution and in vivo binding of the atypical antipsychotic drug remoxipride. A biochemical and autoradiographic analysis in the rat brain

  2005cited by this paper
• NCQ 298, a new selective iodinated salicylamide ligand for the labelling of dopamine D2 receptors

  2005cited by this paper
• The selective dopamine D2 receptor antagonist raclopride discriminates between dopamine-mediated motor functions

  2004cited by this paper
• Stereoselective binding of 11C-raclopride in living human brain — a search for extrastriatal central D2-dopamine receptors by PET

  2004cited by this paper
• In vivo imaging of D2 dopamine receptors in schizophrenia: the ups and downs of neuroimaging research.

  2002cited by this paper
• Experience with indium-111 and yttrium-90-labeled somatostatin analogs.

  2002cited by this paper
• Positron emission tomography and brain monoamine neurotransmission -- entries for study of drug interactions.

  2002cited by this paper
• Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis.

  2001cited by this paper
• Substructure and whole molecule approaches for calculating log P

  2001cited by this paper
• In Vivo Extrastriatal and Striatal D2 Dopamine Receptor Blockade by Amisulpride in Schizophrenia

  2001cited by this paper
• PET studies with carbon-11 radioligands in neuropsychopharmacological drug development.

  2001cited by this paper
• An admonition when measuring the lipophilicity of radiotracers using counting techniques.

  2001cited by this paper
• Brain radioligands--state of the art and new trends.

  2001cited by this paper
• Metabolism of [123I]epidepride may affect brain dopamine D2 receptor imaging with single-photon emission tomography

  2000cited by this paper
• Quantitation of striatal and extrastriatal D‐2 dopamine receptors using PET imaging of [18F]fallypride in nonhuman primates

  2000cited by this paper
• Effect of amphetamine on extrastriatal D2 dopamine receptor binding in the primate brain: A PET study

  2000cited by this paper
• Characterization of 125I‐IABN, a novel azabicyclononane benzamide selective for D2‐like dopamine receptors

  2000cited by this paper
• Dopamine D2 receptor quantification in extrastriatal brain regions using [123I]epidepride with bolus/infusion

  2000cited by this paper
• Imaging Synaptic Neurotransmission with in Vivo Binding Competition Techniques: A Critical Review

  2000cited by this paper
• Preliminary assessment of extrastriatal dopamine D-2 receptor binding in the rodent and nonhuman primate brains using the high affinity radioligand, 18F-fallypride.

  1999cited by this paper
• PET mapping of extrastriatal D2-like dopamine receptors in the human brain using an anatomic standardization technique and [11C]FLB 457.

  1999cited by this paper
• Carbon-11 epidepride: a suitable radioligand for PET investigation of striatal and extrastriatal dopamine D2 receptors.

  1999cited by this paper
• In vivo binding of [11C]nemonapride to sigma receptors in the cortex and cerebellum.

  1999cited by this paper
• Quantification of [11C]FLB 457 Binding to Extrastriatal Dopamine Receptors in the Human Brain

  1999cited by this paper
• PET Imaging of Dopamine D2 Receptors with [18F]Fluoroclebopride in Monkeys: Effects of Isoflurane- and Ketamine-Induced Anesthesia

  1999cited by this paper
• Absolute quantitation of iodine-123 epidepride kinetics using single-photon emission tomography: comparison with carbon-11 epidepride and positron emission tomography

  1999cited by this paper
• Loss of Dopamine D2 Receptors in Alzheimer's Disease with Parkinsonism But Not Parkinson's or Alzheimer's Disease

  1998cited by this paper
• Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.

  1997cited by this paper
• A PET-study of [11C]FLB 457 binding to extrastriatal D2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients

  1997cited by this paper
• In vivo effects of remoxipride and aromatic ring metabolites in the rat.

  1997cited by this paper
• Striatal and extrastriatal imaging of dopamine D2 receptors in the living human brain with [123I]epidepride single-photon emission tomography

  1997cited by this paper
• A single photon emission computed tomography scan study of striatal dopamine D2 receptor binding with 123I-epidepride in patients with schizophrenia and controls.

  1997cited by this paper
• Autoradiographic comparison of [125I]epidepride and [125I]NCQ 298 binding to human brain extrastriated dopamine receptors.

  1997cited by this paper
• Comparison of two fluorine‐18 labeled benzamide derivatives that bind reversibly to dopamine D2 receptors: In vitro binding studies and positron emission tomography

  1996cited by this paper
• Synthesis, in vitro binding profile and biodistribution of a 125I-labeled N-benzyl pyrrolidinyl benzamide derivative: a potential radioligand for mapping dopamine D2 receptors.

  1996cited by this paper
• [18F]haloperidol binding in baboon brain in vivo.

  1996cited by this paper
• Autoradiographic localization of extrastriatal D2‐dopamine receptors in the human brain using [125I]epidepride

  1996cited by this paper
• Critical reevaluation of spiperone and benzamide binding to dopamine D2 receptors: evidence for identical binding sites.

  1996cited by this paper
• Preparation of [76Br]FLB 457 and [76Br]FLB 463 for examination of striatal and extrastriatal dopamine D-2 receptors with PET.

  1996cited by this paper
• Dosimetry of a D2/D3 dopamine receptor antagonist that can be used with PET or SPECT.

  1995cited by this paper
• In vitro and in vivo characterization of R(+)-FIDA2: a dopamine D2-like imaging agent.

  1995cited by this paper
• Lack of Discrimination by Agonists for D2 and D3 Dopamine Receptors

  1995cited by this paper
• Fluorinated benzamide neuroleptics--III. Development of (S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3-[18F]fluoropropyl)-2, 3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer.

  1995cited by this paper
• In vitro receptor binding characteristics of the new dopamine D2 antagonist [125I]NCQ-298: methodological considerations of high affinity binding.

  1995cited by this paper
• Iodine-123-IBF SPECT evaluation of extrapyramidal diseases.

  1995cited by this paper
• Pet imaging studies of dopamine D2 receptors: Comparison of [18F]N‐Methylspiperone; and the benzamide analogues [18F]MABN and [18F]MBP in baboon brain

  1995cited by this paper
• SPECT imaging of dopamine D2 receptors with 2'-iodospiperone.

  1995cited by this paper
• Fluorine-18-labelled NCQ 115, a selective dopamine D-2 receptor ligand. Preparation and positron emission tomography.

  1994cited by this paper
• Aromatic and amine substituent effects on the apparent lipophilicities of N-[(2-pyrrolidinyl)methyl]-substituted benzamides.

  1994cited by this paper
• Synthesis and biodistribution of [5-131I]iodotropapride: a potential D2 dopamine receptor imaging agent.

  1994cited by this paper
• Comparison of three high affinity SPECT radiotracers for the dopamine D2 receptor.

  1994cited by this paper
• Evaluation of 5‐[18F]Fluoropropylepidepride as a potential pet radioligand for imaging dopamine D2 receptors

  1993cited by this paper
• High affinity dopamine D2 receptor radioligands. 3. [123I] and [125I]epidepride: in vivo studies in rhesus monkey brain and comparison with in vitro pharmacokinetics in rat brain.

  1993cited by this paper
• Identification of extrastriatal dopamine D2 receptors in post mortem human brain with [125I]epidepride.

  1993cited by this paper
• New fluorinated dopamine D2 ligands with benzofuran skeleton. The synthesis and in vitro evaluation.

  1993cited by this paper
• Binding characteristics of remoxipride and its metabolites to dopamine D2 and D3 receptors.

  1993cited by this paper
• Effects of remoxipride's metabolites on dopamine D2 receptors and receptor functions in the rat.

  1993cited by this paper
• Failure of the three compartment model to describe the pharmacokinetics in brain of a high affinity substituted benzamide

  1993cited by this paper
• Fluorinated and iodinated dopamine agents: D2 imaging agents for PET and SPECT.

  1993cited by this paper
• Localization of IBF as a D-2 dopamine receptor imaging agent in nonhuman primates

  1993cited by this paper
• Tolerability of Remoxipride in the Long Term Treatment of Schizophrenia

  1993cited by this paper
• Disposition of remoxipride in different species. Species differences in metabolism.

  1993cited by this paper
• 18F-labeled benzamides for studying the dopamine D2 receptor with positron emission tomography.

  1993cited by this paper
• Positron-emitting N-[18F]fluoroalkyl and [18F]fluoropyrrolidinyl analogues of eticlopride as potential in vivo radioligands for dopamine D2 receptors.

  1992cited by this paper
• In vivo studies of [125I]iodobenzamide and [11C]iodobenzamide: A ligand suitable for positron emission tomography and single photon emission tomography imaging of cerebral D2 dopamine receptors

  1992cited by this paper
• PET radioligands for dopamine receptors and re-uptake sites: chemistry and biochemistry.

  1992cited by this paper
• PLS-based quantitative structure-activity relationship for substituted benzamides of clebopride type. Application of experimental design in drug design.

  1992cited by this paper
• Extrastriatal dopamine D2 receptors: distribution, pharmacological characterization and region-specific regulation by clozapine.

  1992cited by this paper
• Visualization of extrastriatal dopamine D2 receptors in the human brain.

  1992cited by this paper
• The current status of PET scanning with respect to schizophrenia.

  1992cited by this paper
• Visualization of dopamine D3-like receptors in human brain with [125I]epidepride.

  1992cited by this paper
• Potential antipsychotic agents. 9. Synthesis and stereoselective dopamine D-2 receptor blockade of a potent class of substituted (R)-N-[(1-benzyl-2-pyrrolidinyl)methyl]benzamides. Relations to other side chain congeners.

  1991cited by this paper
• Dopamine D2 receptors in the rat, monkey and the post-mortem human hippocampus. An autoradiographic study using the novel D2-selective ligand 125I-NCQ 298.

  1991cited by this paper
• Synthesis and in vitro evaluation of 2,3-dimethoxy-5-(fluoroalkyl)-substituted benzamides: high-affinity ligands for CNS dopamine D2 receptors.

  1991cited by this paper
• Characterization and distribution of [125I]epidepride binding to dopamine D2 receptors in basal ganglia and cortex of human brain.

  1991cited by this paper
• High affinity dopamine D2 receptor radioligands. 1. Regional rat brain distribution of iodinated benzamides.

  1991cited by this paper
• D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride.

  1990cited by this paper
• Syntheses of [123I]-, [125I]- and unlabelled (S)-3-iodo-5,6-dimethoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl]salicylamide (NCQ 298), selective ligands for the study of dopamine D-2 receptors.

  1990cited by this paper
• Synthesis and characterization of iodobenzamide analogues: potential D-2 dopamine receptor imaging agents.

  1990cited by this paper
• Optically active benzamides as predictive tools for mapping the dopamine D2 receptor.

  1990cited by this paper
• Potential antipsychotic agents 5. Synthesis and antidopaminergic properties of substituted 5,6-dimethoxysalicylamides and related compounds.

  1990cited by this paper
• Dopamine D-2 receptors imaged by PET in Cebus apella using [18F]benzamide neuroleptic.

  1990cited by this paper
• The characterization of IBF as a new selective dopamine D-2 receptor imaging agent.

  1990cited by this paper
• In vivo SPECT imaging of CNS D-2 dopamine receptors: initial studies with iodine-123-IBZM in humans.

  1990cited by this paper
• Clinical pharmacokinetics of remoxipride

  1990cited by this paper
• Potential antipsychotic agents. 7. Synthesis and antidopaminergic properties of the atypical highly potent (S)-5-bromo-2,3-dimethoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl]benzamide and related compounds. A comparative study.

  1990cited by this paper
• N-fluoroalkylated and N-alkylated analogues of the dopaminergic D-2 receptor antagonist raclopride.

  1990cited by this paper
• PET imaging of dopamine receptors in human basal ganglia: relevance to mental illness.

  1990cited by this paper
• Endogenous dopamine lowers the dopamine D2 receptor density as measured by [3H]raclopride: Implications for positron emission tomography of the human brain

  1989cited by this paper
• D2-dopamine receptor specific brain uptake of carbon-11-labeled YM-09151-2.

  1989cited by this paper
• (S)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-[125I]iodo- 2-methoxybenzamide hydrochloride, a new selective radioligand for dopamine D-2 receptors.

  1988cited by this paper
• Dopamine D-2 receptor imaging radiopharmaceuticals: synthesis, radiolabeling, and in vitro binding of (R)-(+)- and (S)-(-)-3-iodo-2-hydroxy-6-methoxy-N- [(1-ethyl-2-pyrrolidinyl)methyl]benzamide.

  1988cited by this paper
• [125I]iodopride: a specific high affinity radioligand for labelling striatal dopamine D-2 receptors.

  1988cited by this paper
• New selective dopamine D-2 antagonists as antipsychotic agents. Pharmacological, chemical, structural and theoretical considerations.

  1987cited by this paper
• Solid state conformations and antidopaminergic effects of remoxipride hydrochloride and a closely related salicylamide, FLA 797, in relation to dopamine receptor models.

  1986cited by this paper
• Potential neuroleptic agents. 4. Chemistry, behavioral pharmacology, and inhibition of [3H]spiperone binding of 3,5-disubstituted N-[(1-ethyl-2-pyrrolidinyl)methyl]-6-methoxysalicylamides.

  1986cited by this paper
• Uptake of 77Br‐spiperone in the striata of schizophrenic patients and controls

  1986cited by this paper
• Molecular electrostatic potential of orthopramides: implications for their interaction with the D-2 dopamine receptor.

  1986cited by this paper

• Design and Synthesis of D3R Bitopic Ligands with Flexible Secondary Binding Fragments: Radioligand Binding and Computational Chemistry Studies

  2023cites this paper
• 11C- and 18F-Radiotracers for In Vivo Imaging of the Dopamine System: Past, Present and Future

  2021cites this paper
• Low convergent validity of [11C]raclopride binding in extrastriatal brain regions: a PET study of within-subject correlations with [11C]FLB 457

  2020cites this paper
• In vivo absolute quantification of striatal and extrastriatal D2/3 receptors with [123I]epidepride SPECT

  2020cites this paper
• Evaluation of radiotracers for beta cell imaging

  2017cites this paper
• SPECT of Transplanted Islets of Langerhans by Dopamine 2 Receptor Targeting in a Rat Model.

  2016cites this paper
• Imaging the Biodistribution and Performance of Transplanted Stem Cells with PET

  2016cites this paper
• Exploring receptor targeting as a tool for preclinical in vivo imaging of the islets of Langerhans

  2016cites this paper
• ¹²⁴I-Epidepride: a PET radiotracer for extended imaging of dopamine D2/D3 receptors.

  2014cites this paper
• Batch-reactor microfluidic device: first human use of a microfluidically produced PET radiotracer.

  2013cites this paper
• Synthesis and biological evaluation of 18F-Norfallypride in the rodent brain using PET imaging.

  2013cites this paper
• Molecular imaging PET and SPECT approaches for improving productivity of antipsychotic drug discovery and development.

  2013cites this paper
• Biomarkers for trials of neuroprotection in Parkinson's disease

  2013cites this paper
• t-Bu2SiF-Derivatized D2-Receptor Ligands: The First SiFA-Containing Small Molecule Radiotracers for Target-Specific PET-Imaging

  2011cites this paper
• Advances in the Role of Neuroimaging to Monitor Disease Progression in Parkinson’s Disease

  2011cites this paper
• Imaging the nigrostriatal system to monitor disease progression and treatment-induced complications.

  2010cites this paper
• Design, synthesis, and binding affinities of potential positron emission tomography (PET) ligands with optimal lipophilicity for brain imaging of the dopamine D3 receptor. Part II.

  2009cites this paper
• 99mTc-TRODAT-1 and 123I-IBZM SPECT studies in a patient with extrapontine myelinolysis with parkinsonian features

  2009cites this paper
• A Review of the Discovery, Pharmacological Characterization, and Behavioral Effects of the Dopamine D2‐Like Receptor Antagonist Eticlopride

  2008influential citation
• A new multi-gram synthetic route to labeling precursors for the D(2/3) PET agent 18F-fallypride.

  2008cites this paper
• Discovery of (-)-7-methyl-2-exo-[3'-(6-[18F]fluoropyridin-2-yl)-5'-pyridinyl]-7-azabicyclo[2.2.1]heptane, a radiolabeled antagonist for cerebral nicotinic acetylcholine receptor (alpha4beta2-nAChR) with optimal positron emission tomography imaging properties.

  2008cites this paper
• Positron emission tomography ligand activation studies in the sports sciences: measuring neurochemistry in vivo.

  2008cites this paper
• Development of radioligands for in vivo imaging of type 1 cannabinoid receptors (CB1) in human brain.

  2008cites this paper
• In vitro affinities of various halogenated benzamide derivatives as potential radioligands for non-invasive quantification of D(2)-like dopamine receptors.

  2007cites this paper
• Update: Aptamers as Novel Radiopharmaceuticals: Their Applications and Future Prospects in Diagnosis and Therapy

  2007cites this paper
• Quantification of PET Studies with the Very High-Affinity Dopamine D2/D3 Receptor Ligand [11C]FLB 457: Re-Evaluation of the Validity of using a Cerebellar Reference Region

  2007cites this paper
• [123I]Epidepride binding to cerebellar dopamine D2/D3 receptors is displaceable: Implications for the use of cerebellum as a reference region

  2007cites this paper
• The quest for Eldorado: development of radioligands for in vivo imaging of nicotinic acetylcholine receptors in human brain.

  2006cites this paper
• Measuring dopamine neuromodulation in the thalamus: Using [F-18]fallypride PET to study dopamine release during a spatial attention task

  2006influential citation
• Design, synthesis, and binding affinities of potential positron emission tomography (PET) ligands for visualization of brain dopamine D3 receptors.

  2006cites this paper
• Chemical toxicology: reactive intermediates and their role in pharmacology and toxicology

  2006cites this paper
• Effect of reduction in endogenous dopamine on extrastriatal binding of [11C]FLB 457 in rat brain—An ex vivo study

  2006cites this paper
• PET imaging in clinical drug abuse research.

  2005cites this paper
• PET and SPECT exploration of central monoaminergic transporters for the development of new drugs and treatments in brain disorders.

  2005cites this paper
• Weaving Single Photon Imaging into New Drug Development

  2005cites this paper
• 5-substituted derivatives of 6-halogeno-3-((2-(S)-azetidinyl)methoxy)pyridine and 6-halogeno-3-((2-(S)-pyrrolidinyl)methoxy)pyridine with low picomolar affinity for alpha4beta2 nicotinic acetylcholine receptor and wide range of lipophilicity: potential probes for imaging with positron emission tomog

  2004cites this paper
• PET imaging of beta-adrenoceptors in human brain: a realistic goal or a mirage?

  2004cites this paper
• Antipsychotic polypharmacy.

  2004cites this paper
• Imaging drug resistance with radiolabeled molecules.

  2004cites this paper
• Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?

  2004cites this paper